Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 005083100 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Voss Capital, LP
13G/A
Amendment 1
|
7.7% |
4/22/2026
Event 3/31/2026
|
|
| Voss Capital, LP | 7.7% | ||
| Cocke Travis W. | 7.7% | ||
| Voss Advisors GP, LLC | 1.5% | ||
| Voss Value Master Fund, LP | 1.3% | ||
| Voss Value-Oriented Special Situations Fund, LP | 0.2% | ||
|
Voss Capital, LP
13G
|
5.3% |
12/17/2025
Event 12/15/2025
|
|
| Voss Capital, LP | 5.3% | ||
| Cocke Travis W. | 5.3% | ||
| Voss Advisors GP, LLC | 1.1% | ||
| Voss Value Master Fund, LP | 0.9% | ||
| Voss Value-Oriented Special Situations Fund, LP | 0.2% | ||
|
BIOS Fund I, LP
13D/A
Amendment 2
|
49.8% |
6/30/2025
Event 6/27/2025
|
|
| Bios Fund I, LP | 2.6% | ||
| Bios Fund I QP, LP | 1.5% | ||
| Bios Fund II, LP | 1.5% | ||
| Bios Fund II QP, LP | 4.9% | ||
| Bios Fund II NT, LP | 0.7% | ||
| Bios Fund III, LP | 1.9% | ||
| Bios Fund III QP, LP | 12.3% | ||
| Bios Fund III NT, LP | 2.0% | ||
| BP Directors, LP | 0.6% | ||
| Bios Actuate Co-Invest I, LP | 1.5% | ||
| Bios Actuate Co-Invest II, LP | 10.2% | ||
| Bios Actuate Co-Invest III, LP | 2.8% | ||
| Bios Clinical Opportunity Fund, LP | 6.2% | ||
| Bios 2024 Co-Invest, LP | 1.3% | ||
| Bios Equity Partners, LP | 4.6% | ||
| Bios Equity Partners II, LP | 8.5% | ||
| Bios Equity Partners III, LP | 29.2% | ||
| Bios Equity Cof, LP | 7.4% | ||
| Cavu Management, LP | 42.2% | ||
| Bios Capital Management, LP | 49.5% | ||
| Cavu Advisors, LLC | 42.2% | ||
| Bios Advisors GP, LLC | 49.5% | ||
| Leslie W. Kreis | 42.6% | ||
| Aaron G.L. Fletcher | 49.8% | ||
|
BIOS Fund I, LP
13D/A
Amendment 1
|
51.3% |
5/27/2025
Event 5/22/2025
|
|
| Bios Fund I, LP | 2.7% | ||
| Bios Fund I QP, LP | 1.6% | ||
| Bios Fund II, LP | 1.6% | ||
| Bios Fund II QP, LP | 5.1% | ||
| Bios Fund II NT, LP | 0.7% | ||
| Bios Fund III, LP | 2.0% | ||
| Bios Fund III QP, LP | 12.8% | ||
| Bios Fund III NT, LP | 2.1% | ||
| BP Directors, LP | 0.6% | ||
| Bios Actuate Co-Invest I, LP | 1.5% | ||
| Bios Actuate Co-Invest II, LP | 10.7% | ||
| Bios Actuate Co-Invest III, LP | 2.9% | ||
| Bios Clinical Opportunity Fund, LP | 6.4% | ||
| Bios 2024 Co-Invest, LP | 0.6% | ||
| Bios Equity Partners, LP | 4.8% | ||
| Bios Equity Partners II, LP | 8.9% | ||
| Bios Equity Partners III, LP | 30.4% | ||
| Bios Equity Cof, LP | 7.1% | ||
| Cavu Management, LP | 44.0% | ||
| Bios Capital Management, LP | 51.0% | ||
| Cavu Advisors, LLC | 44.0% | ||
| Bios Advisors GP, LLC | 52.4% | ||
| Leslie W. Kreis | 44.4% | ||
| Aaron G.L. Fletcher | 51.3% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 29.0 k | $22.6 k |
| 2026 Q2 | 63 | 13.5 M | $20.7 M |
| 2026 Q1 | 62 | 13.9 M | $38.0 M |
| 2025 Q4 | 45 | 13.1 M | $80.2 M |
| 2025 Q3 | 44 | 12.0 M | $80.5 M |
| 2025 Q2 | 40 | 11.2 M | $68.6 M |
| 2025 Q1 | 26 | 10.4 M | $70.4 M |
| 2024 Q4 | 20 | 10.1 M | $80.5 M |
| 2024 Q3 | 11 | 382 k | $2.85 M |